Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk ...

As the Affordable Care Act passed its 15th anniversary this year, Supreme Court Justices continue to deliberate the fate of ...

John Michael O'Brien, PharmD, MPH, discussed the changes in managed care over the past 30 years to commemorate the 30th ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't ...

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic ...

Panelists discuss how newer urinary tract infection (UTI) therapies such as pivmecillinam, sulopenem etzadroxil/probenecid, and gepotidacin demonstrate significantly lower resistance rates (below 5%) ...

Experts discuss how to evaluate the cost-effectiveness of continuous glucose monitoring (CGM) compared to traditional monitoring, considering both clinical and quality outcomes, and what combination ...

Experts share specific examples of how continuous glucose monitoring (CGM) technology has impacted diabetes-related health care costs and quality performance metrics, and discuss the methods used to ...

Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE ...

Panelists discuss how developing effective management protocols for amyloid-related imaging abnormalities (ARIA) requires implementing robust baseline and follow-up MRI monitoring schedules, ...